Yasmeen Rahimi, an analyst from Piper Sandler, has initiated a new Buy rating on Tenax Therapeutics (TENX).
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yasmeen Rahimi’s rating is based on the promising potential of Tenax Therapeutics’ TNX-103, which is being developed for the treatment of Group 2 PH-HFpEF. The drug’s unique mechanism as a dual K+ ATP channel activator and calcium sensitizer offers a compelling therapeutic approach, addressing key aspects of the disease’s pathophysiology. The positive results from Phase 2 trials, including improvements in hemodynamics and exercise capacity, further bolster confidence in its efficacy and safety.
Moreover, the upcoming Phase 3 LEVEL trial, expected to provide results in the second half of 2026, is seen as a significant catalyst for the stock. The trial is designed with robust statistical power to detect meaningful improvements in the primary endpoint, which, if successful, could lead to regulatory approval in a market with high unmet needs. These factors contribute to the Buy rating, reflecting the potential for substantial future growth in Tenax Therapeutics’ stock value.